Agluna is a patented surface modification technology applied to medical devices manufactured from titanium and its various alloys, to reduce bacterial infection rates following surgical procedures.

Under the terms of the agreement, Zimmer will acquire exclusive global rights to utilise Agluna for joint reconstruction and trauma products and also an 18-month option to acquire additional rights for spinal devices, dental implants and sports medicine products.

Additionally, both Accentus and Zimmer collaborate to secure regulatory approval for products treated with the Agluna technology in both the EU and US.

Accentus Medical CEO Philip Agg said that the agreement represents a significant step forward for the company, and they are very pleased to be working with Zimmer.

“Having invested significant resources in developing the technology and in generating a large amount of evidence supporting its safety and efficacy, the company is in a position to fully commercialise and exploit the Agluna technology,” Agg said.